|Application ||WB, IHC-P, IF, E|
|Other Accession||AAC41702, 184623|
|Calculated MW||22294 Da|
|Application Notes||IFN-b antibody can be used for detection of IFN-b by Western blot at 5 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Reconstitution & Storage||IFN-beta antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||IFN-beta Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Has antiviral, antibacterial and anticancer activities.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IFN-beta Antibody: Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by "Natural IFN-producing cells" (IPCs) as part of the host immune response and can also inhibit the development of tumors. IFN-beta binding by its receptor results in the activation of the tyrosine kinases Jak1 and Tyk2 and phosphorylation of members of the STAT family of transcription factors, leading to the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.
Gresser I. Wherefore interferon? J. Leuk. Biol.1997; 61:567-74.
Colonna M. TLR pathways and IFN-regulatory factors: to each its own. Eur. J. Immunol.2007; 37:306-9.
Kock M, Mostert J, De Keyser J, et al. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis. Ann. Neurol.2007; epub.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.